TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
Ikena Oncology has shared that on December 14th, 2023, the Food and Drug Administration (FDA) granted Orphan Drug Designation to IK-930 for the treatment of epithelioid hemangioendothelioma (EHE). We are excited about this designation following initial positive data from the IK-930 Phase I clinical trial published in Ikena’s November 9th press release. What does this […]
Read MoreThank you! Together, we raised more than $160,000 to fund critically needed research into epithelioid hemangioendothelioma (EHE). Rare cancers, like EHE, lack sufficient governmental and pharmaceutical funding sources available for more common cancers. Your donations support our work to level the playing field. A special thanks to: Thank you for joining us in our fight […]
Read MoreThe EHE Foundation awards research grants to advance our mission to find treatments and a cure for EHE. With the guidance of our Research Committee, Advisory Board, and expert reviewers, we are pleased to announce the research grants awarded in 2023: Ajaybabu Pobbati, PhD, Cleveland Clinic Lerner Research Institute Harnessing FDA-approved drugs to gain mechanistic […]
Read MoreBrianna Carney was only 23 when she passed on December 26, 2022. She was full of life and lived it to the fullest. She was passionate about those she loved, her dogs, rescuing other dogs, helping people, and being the best version of herself through hard work. She was a first-generation graduate of Nova Southeastern […]
Read MoreThe EHE Foundation was founded by patients, for patients. Continuing that tradition, we aredelighted to announce that EHE patient John McFadden, Ph.D., CRNA, APRN, has joined ourBoard of Directors. With more than 35 years of experience in health care, Dr. McFadden has held positions as anurse executive, hospital and university program accreditation surveyor, faculty member, […]
Read More